biotechnology


/R E P E A T – Nova Mentis and KGK Science Form Tactical Partnership/

January 27th, 2022 - Ryan Allway

The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application to Health Canada   VANCOUVER, BC, Jan. 27, 2022 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that the Company has […]

West Island Closes on 1st Tranche of Private Placement

January 25th, 2022 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – January 25, 2022) – West Island Brands Inc. (CSE: WIB) (FSE: 39N0) (OTCQB: WIBFF) (“West Island” or the “Company”) is pleased to announce that it has the first tranche a non-brokered private placement consisting of 1,080,000 units at a price of $0.25 per unit for aggregate gross proceeds of $270,000.00. Each unit is […]

Rapid Dose Therapeutics Strengthens Leadership Team with Addition of Rodney Butt & Appoints New Advisory Board Member

December 15th, 2021 - Ryan Allway

Additions to support immediate commercialization efforts for the Company’s COVID-19 vaccine candidate   BURLINGTON, Ontario, December 15, 2021–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company“) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, is pleased to announce a significant addition to the Company’s leadership team with the appointment of Rodney Butt […]

Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies

December 7th, 2021 - Ryan Allway

TAMPA, FLA. (PRWEB) DECEMBER 07, 2021 Psilera Inc. (“Psilera”), a Florida-based biotechnology company developing non-hallucinogenic derivatives of psychedelic compounds and outpatient delivery methods for the treatment of anxiety, substance abuse, and PTSD, is thrilled to receive positive results from in vivo preclinical studies. A modified DMT derivative, PSIL-002, was safe, well-tolerated, and without hallucinogenic effects at all […]

Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules

November 24th, 2021 - Ryan Allway

MIAMI BEACH, Fla., Nov. 24, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that it has entered into securities purchase agreements with certain institutional investors to purchase 8.68 […]

Clearmind Medicine Files Provisional Patent Application Related to Methods of Drug-Assisted Psychotherapy

October 13th, 2021 - Ryan Allway

TORONTO, Ontario, Oct. 13, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announces that it has filed a provisional patent application (PPA) with the United […]

Skye Bioscience Establishes New Cannabinoid Pharmaceutical Innovation Program

October 12th, 2021 - Ryan Allway

SAN DIEGO, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has formed a new exclusive sponsored research agreement with Emerald Health Biotechnology Espana SLU (“EHBE”), focused on developing and […]

Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development

October 1st, 2021 - Ryan Allway

TORONTO, October 01, 2021–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company“), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce: the addition of Dr. Amir Inamdar as its Chief Medical Officer for its European Operations, the addition of Dr. Geoff Varty as its new Head of Research & Development, the promotion […]

PharmaTher Added to the North American Psychedelics Index and First Psychedelic Exchange Traded Fund

September 21st, 2021 - Ryan Allway

TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that the Company has been included to the North American Psychedelics Index, (the “Index”), which is the underlying index of the Horizons Psychedelic Stock Index Exchange Traded Fund […]

Willow Biosciences Announces Commercial Scale Operational Update, CBGA Production Update and Corporate Update

September 21st, 2021 - Ryan Allway

VANCOUVER, BC, Sept. 21, 2021 /PRNewswire/ – Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW) (OTCQX: CANSF), a leading biotechnology company that manufactures ultra-pure, sustainably produced cannabinoids via yeast-based biosynthesis, is pleased to provide the following operational and corporate updates.   Commercial Scale Operational Update In March 2021, Willow completed its first commercial scale fermentation run of […]

Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update

August 26th, 2021 - Ryan Allway

PETACH TIKVA, Israel, August 26, 2021–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended June 30, 2021.   Corporate and Clinical Development Highlights Include: Can-Fite Entered into Development and […]

Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity

August 18th, 2021 - Ryan Allway

— BMB proprietary 5-HT2C agonist, BMB-101, shows efficacy in pre-clinical models of Dravet Syndrome/Epilepsy, with lower seizure duration and frequency — — Effect of BMB compounds was consistent with other anti-epileptics such as fenfluramine —     VANCOUVER, British Columbia, Aug. 18, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: […]

Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5

July 28th, 2021 - Ryan Allway

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received approval for the listing of its common shares on the NYSE American LLC stock exchange (“NYSE American”). The Company expects its common shares will open for trading on the NYSE American on or […]

BioHarvest Sciences Inc. Demonstrates Industry Leading Sustainability Credentials With Inaugural Environmental Sustainability Report

July 15th, 2021 - Ryan Allway

First biotechnology company engaged in the production of Cannabis biomass and cannabinoids to publish an ESG report and commit to tangible, science-based targets BioFarming manufacturing process uses 99.99% less land than traditional outdoor agriculture, while generating no direct greenhouse gases “GHG” emissions, no hazardous waste, and producing 100% biodegradable wastewater Committed to further reducing its environmental footprint while scaling production Directly […]

EVIO, Inc. Enters into Letter of Intent to Acquire Leading Edge Pharms, Inc.

July 14th, 2021 - Ryan Allway

EVIO Inc. (OTC: EVIO) is pleased to announce that is has entered into a Letter of Intent to acquire Leading Edge Pharms, Inc. (LEP) of Henderson, Nevada. LEP is a biotechnology company focused on the research, development, and commercialization of novel cannabinoid therapies and innovative drug delivery systems that provide safe and effective topical solutions for […]

Cybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy

July 13th, 2021 - Ryan Allway

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed its 13th new provisional patent application and has advanced the build-out of its digital therapeutics strategy.   The company is evolving its programs beyond the psychedelic molecule, into an eco-system that may potentially drive […]

BetterLife Provides H1 2021 Progress Update

July 12th, 2021 - Ryan Allway

VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, announces significant progress in H1 2021.   TD-0148A BetterLife’s TD-0148A is a second-generation lysergic acid diethylamide (“LSD”) derivative molecule that has been synthesized […]

22nd Century Announces $40 Million Common Stock Registered Direct Offering

June 7th, 2021 - Ryan Allway

Financing Provides Support to the Company’s Strategic Objectives Across All Its Plant Franchises.   BUFFALO, N.Y., June 07, 2021 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and hemp/cannabis research, today announced that it has entered into a definitive agreement with […]

AIkido Pharma Announces Positive Phase 1 Data Presented at ASCO on 225Ac-J591

June 4th, 2021 - Ryan Allway

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients – Phase 2 Trial Underway   NEW YORK, June 4, 2021 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4, 2021.  The poster presentation of the data was […]

BetterLife Pharma Appoints Henri Sant-Cassia of The Conscious Fund to its Board of Directors

June 2nd, 2021 - Ryan Allway

VANCOUVER, British Columbia, June 02, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce that it has appointed Mr. Henri Sant-Cassia, co-founder of The Conscious Fund, to its Board of Directors.   Mr. Sant-Cassia has 10 […]

Gilgamesh Pharmaceuticals Closes On $27 Million Series A Round

May 6th, 2021 - Ryan Allway

NEW YORK, May 6, 2021 /PRNewswire/ — Gilgamesh Pharmaceuticals, a mental health science focused biotechnology company utilizing psychedelic-related medicines for the treatment of neuropsychiatric conditions, today announced the closing of a $27 million Series A round of funding led by Prime Movers Lab, an investor in breakthrough scientific startups working to revolutionize the world’s most important industries and transform […]

Entheon Biomedical Lists on OTCQB Venture Market

May 5th, 2021 - Ryan Allway

Vancouver, BC – May 5, 2021 – Entheon Biomedical Corp. (CSE: “ENBI”; OTCQB: “ENTBF”; FSE: “1XU1”) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has been approved for trading on the OTCQB Venture Market (“OTCQB”) effective May 5, 2021.   “We are […]

Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications

April 13th, 2021 - Ryan Allway

TORONTO-April 13, 2021-(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced plans to advance the pre-clinical work for its orally dissolving tablet (“ODT”) formulation of CYB003 and its inhaled formulation of CYB004, two of the Company’s deuterated tryptamine development candidates. These studies are part of the […]

Havn Life Completes Acquisition of Strategic Manufacturing & Packaging Facility for its Retail Division

April 8th, 2021 - Ryan Allway

The Facility acquisition positions Havn Life to quickly expand its product portfolio and reach additional NHP categories.   VANCOUVER, BC / ACCESSWIRE / April 8, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (“Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce, further to […]

Core One Labs Vocan Expands Product Commercialization Team

April 6th, 2021 - Ryan Allway

VANCOUVER, BC / ACCESSWIRE / April 6, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (“Core One“) is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Vocan“) has expanded its product commercialization team, adding Dr. Elizabeth Matthews as Head of Scientific and Regulatory Affairs.   Dr. Matthews will oversee research and development, as well […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading